Holen Sie sich die Stockscreener-App
448.21
0.49%
2.18
Handel nachbörslich:
451.00
2.79
+0.62%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$446.03
Offen:
$448.21
24-Stunden-Volumen:
2.09M
Relative Volume:
0.95
Marktkapitalisierung:
$166.56B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.87B
KGV:
24.64
EPS:
18.1888
Netto-Cashflow:
$6.75B
1W Leistung:
-5.53%
1M Leistung:
-14.99%
6M Leistung:
-22.55%
1J Leistung:
+10.38%
1-Tages-Spanne:
$446.05
$459.18
1-Wochen-Bereich:
$444.52
$473.49
52-Wochen-Spanne:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
448.21 | 165.75B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
164.54 | 117.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
532.86 | 41.70B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
333.21 | 32.89B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
113.26 | 31.86B | 7.07B | 1.29B | 993.00M | 4.5355 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher (TMO) Coverage Resumed with Sector Perform Rating - GuruFocus
RBC Capital assumes Thermo Fisher stock with Sector Perform rating - Investing.com
RBC Capital assumes Thermo Fisher stock with Sector Perform rating By Investing.com - Investing.com Canada
Ex-Investor Seeks Records On $8.9B Thermo Fisher Payout - Law360
Thermo Fisher Scientific stock (US8835561023): Q1 earnings beat with EPS of $5.44 - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Nuvation Bio Completes IBTROZI Manufacturing Tech Transfer to Thermo Fisher - Contract Pharma
Bioinformatics Platforms Market Is Going to Boom | • Illumina Inc • Thermo Fisher Scientific Inc • QIAGEN N.V - openPR.com
Nuvation Bio stock (US55043Q1004): Manufacturing deal with Thermo Fisher for lung cancer drug - AD HOC NEWS
Cell Cryopreservation Market 2026- 2033 Overview: Share, Size, - openPR.com
Thermo Fisher Scientific stock (US8835561023): Q1 earnings beat signals strength in life sciences - AD HOC NEWS
Between Mettler-Toledo International and Thermo Fisher Scientific, Which Stock Looks Set to Break Out? - Trefis
Thermo Fisher (TMO) Completes Tech Transfer for Ibtrozi - GuruFocus
Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market - MarketWatch
Nuvation Bio partners with Thermo Fisher for US drug manufacturing - Investing.com
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
Thermo Fisher Sci. stock (US8835561023): Recent earnings beat and price gain - AD HOC NEWS
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Sci. stock (US8835561023): Leader in life sciences tools - AD HOC NEWS
Nucleic Acid Isolation and Purification Market Report 2026-2030: Trends, Challenges and Competitive Analysis Featuring Thermo Fisher Scientific, Merck, QIAGEN, and Roche - Yahoo Finance
Westpac Banking Corp's Thermo Fisher Scientific Inc(TMO) Holding History - GuruFocus
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S Cash Flow – TSX:TMO - TradingView
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S - TradingView
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S Balance Sheet – TSX:TMO - TradingView
Thermo Fisher Expands Cell Therapy And Hydration Platforms To Deepen Ecosystem - Yahoo Finance
Thermo Fisher Scientific : Additional Soliciting Materials - marketscreener.com
Thermo Fisher Sci. stock (US8835561023): Q1 2026 earnings beat estimates - AD HOC NEWS
Upstream Bioprocessing Equipment Market Is Going to Boom | Thermo Fisher Scientific, Merck KGaA, Sartorius AG - openPR.com
Thermo Fisher Scientific Inc (TMO): An Investor Outlook with Strong Buy Ratings and Robust Revenue Growth - DirectorsTalk Interviews
Cross-Belt Analyzers Market Size Accelerating at 8.7% CAGR | - openPR.com
Thermo Fisher Scientific acquires Clario for nearly $8.9bn - MSN
Thermo Fisher Sci. stock (US8835561023): Earnings beat and guidance lift drive shares higher - AD HOC NEWS
Jim Cramer on Thermo Fisher: “I Think You Can Buy It at This Level” - Yahoo Finance
Thermo Fisher Scientific Inc. stock falls Friday, underperforms market - MarketWatch
Wells Fargo Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $615 - Moomoo
Thermo Fisher Scientific Launches PackEye™ XS Radiation Detection Backpack: Covert, High-Accuracy Identification in a Lightweight, Mission-Ready Design - AZoSensors
Polystyrene Latex Particle Market Size Advancing at 6.3% CAGR | - openPR.com
Morgan Stanley, Thermo Fisher, Blue Owl Technology Finance and more on CNBC's 'Final Trades' - MSN
Is It Time To Revisit Thermo Fisher Scientific (TMO) After This Year’s Share Price Pullback - Yahoo Finance
Thermo Fisher Scientific Inc. stock rises Wednesday, still underperforms market - MarketWatch
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider - PharmiWeb.com
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials - BioSpace
Thermo Fisher projects 2026 adjusted EPS of $24.64-$25.12 as it raises revenue outlook to $47.3B-$48.1B - MSN
Erste Group Maintains Thermo Fisher Scientific(TMO.US) With Hold Rating - Moomoo
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Billionaire investor takes new stake in Thermo Fisher Scientific - MSN
Thermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor - Contract Pharma
International Markets and Thermo Fisher (TMO): A Deep Dive for Investors - Yahoo Finance
Thermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing - BioPharma APAC
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing - New Castle News
What Is Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Doing? - Yahoo Finance
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):